EZH2 and cancer: In conclusion, the expression of SPRY4-IT1 was significantly decreased in NSCLC tissues, which was at least partially mediated by EZH2, suggesting that its downregulation may be a negative prognostic factor for NSCLC patients, indicative of poor survival rates, and a higher risk for cancer metastasis.